Senseonics Holdings, Inc. (SENS) Stock Price & Analysis
Senseonics Holdings, Inc. (SENS) rose 4.21% to USD 7.43 as of June 10, 2026 at 01:50 UTC, according to Nexqual real-time market data.
SENS last closed at USD 7.13; the session ranged USD 7.06–7.69 on volume of 777,641 shares. Market capitalization is $387.87M, with a 52-week range of USD 4.79–12.58 (NMS). Source: Nexqual, June 10, 2026 at 01:50 UTC.
Key Statistics (as of June 10, 2026 at 01:50 UTC)
| Price | USD 7.43 |
|---|---|
| Change | ▲ 4.21% (up) |
| Previous Close | USD 7.13 |
| Open | USD 7.2 |
| Day Range | USD 7.06 – 7.69 |
| 52-Week Range | USD 4.79 – 12.58 |
| Volume | 777,641 shares |
| Market Cap | $387.87M |
| Exchange | NMS |
Technical Analysis (SENS)
Nexqual's technical model rates SENS "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 01:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.02 (neutral) |
| vs SMA50 | Above (USD 6.39) |
| MACD | 0.27 (positive) |
Analyst Ratings (SENS)
Wall Street analysts rate SENS "Buy" based on 5 analysts, with a mean price target of USD 13.8 (range USD 8–20), per Nexqual as of June 10, 2026 at 01:50 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 13.8 |
| High Target | USD 20 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 4 / 2 / 1 |
Earnings (SENS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.62 |
| Revenue Estimate | $12.90M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.71 vs est -0.7 ▼ miss |
| 2025-12-31 | USD -0.46 vs est -0.43 ▼ miss |
| 2025-09-30 | USD -0.43 vs est -0.4 ▼ miss |
| 2025-06-30 | USD -0.4 vs est -0.4 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:50 UTC.
Financials & Fundamentals (SENS)
| Total Revenue | $35.26M |
|---|---|
| Revenue Growth (YoY) | +71.80% |
| Gross Margin | +44.71% |
| Operating Margin | -146.78% |
| Profit Margin | -196.03% |
| ROE | -168.27% |
| Debt / Equity | 67.77 |
| Current Ratio | 4.83 |
| Total Cash | $94.03M |
| Total Debt | $41.37M |
| Free Cash Flow | $-46.50M |
Source: Nexqual, June 10, 2026 at 01:50 UTC.
Financial Health Score (SENS)
Nexqual rates Senseonics Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:50 UTC.
| Growth | Strong — Revenue +57% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $94M cash vs $41M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$47M, burning cash |
| Efficiency | Critical — ROE -168%, ROA -37.7% |
Ownership (SENS)
| Insider Ownership | +12.59% |
|---|---|
| Institutional Ownership | +21.05% |
| Shares Outstanding | 52.20M |
| Float | 38.52M |
| Short % of Float | +9.05% |
Source: Nexqual, June 10, 2026 at 01:50 UTC.
Leadership (SENS)
Senseonics Holdings, Inc. is led by Timothy T. Goodnow (age 63), President, CEO & Director, per Nexqual as of June 10, 2026 at 01:50 UTC.
| President, CEO & Director | Timothy T. Goodnow (age 63) |
|---|---|
| CFO, Secretary & Treasurer | Frederick T. Sullivan (age 43) |
| Chief Operating Officer | Mukul Jain (age 52) |
| Chief Medical Officer & Director | Francine Ratner Kaufman (age 74) |
| Chief Commercial Officer & Director | Brian B. Hansen (age 57) |
Major Backers & Investors (SENS)
Notable institutional backers of Senseonics Holdings, Inc. include Sessa Capital IM, L.P., Millennium Management, Masters Capital Management, LLC, according to Nexqual as of June 10, 2026 at 01:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sessa Capital IM, L.P. | 4.22% |
| Millennium Management | 1.34% |
| Masters Capital Management, LLC | 1.2% |
| Marshall Wace LLP | 1.11% |
| UBS Group AG | 1.07% |
| Fidelity | 0.82% |
| Susquehanna International Group, LLP | 0.55% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.19% |
| BlackRock | 1.48% |
| Geode Capital | 1.12% |
Source: Nexqual, June 10, 2026 at 01:50 UTC.
From Senseonics Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
- Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
- The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BNGO | Bionano Genomics, Inc. | USD 1.16 | ▼ 0.85% |
| NNDM | Nano Dimension Ltd. | USD 1.49 | ▼ 4.49% |
| OCGN | Ocugen, Inc. | USD 1.24 | ▼ 3.13% |
| CTRM | Castor Maritime Inc. | USD 2.18 | ▲ 2.35% |
| GEVO | Gevo, Inc. | USD 1.5 | ▼ 7.98% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:50 UTC. This page is informational and not investment advice.